NCT07524426 Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment
| NCT ID | NCT07524426 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Umeå University |
| Condition | Bladder Cancer (BC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 248 participants |
| Start Date | 2026-06-03 |
| Primary Completion | 2032-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 248 participants in total. It began in 2026-06-03 with a primary completion date of 2032-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to improve the quality of life and prolong survival in bladder cancer patients unfit for curative treatment. The trial will compare the survival and symptoms of patients randomized to either local radiotherapy in addition to standard of care or standard of care alone. Using modern radiotherapy techniques, including hypofractionation and image-guided treatment adaptation, the aim is to deliver a well-tolerated, time-efficient, and effective treatment strategy for these patients. The trial collaborates with two ongoing exploratory biomarker studies collecting and analyzing potential biomarkers in urothelial bladder cancer. The hope is to provide biomarkers for prognosis and treatment response which is essential to ensure bladder cancer patients individualized treatment in the future, like those with breast and prostate cancer.
Eligibility Criteria
Inclusion Criteria: 1. Oral and written consent 2. Histologically confirmed MIBC with urothelial component 3. Male or female participants ≥ 18 years old 4. Deemed not to benefit from curative treatment at a multidisciplinary tumour conference (MDT) or having declined curative treatment of their own accord. Exclusion Criteria: 1. Clinical Fragility Scale score ≥8 2. Previous pelvic RT with significant overlap 3. Visceral or bone metastases on CT scan 4. Multiple (\>3) lymph node metastases with a measurement of \>2 cm on CT scan 5. Planed for systemic treatment at the time of inclusion. 6. Local RT to the bladder indicated for the palliation of symptoms at the time of inclusion.
Contact & Investigator
Karin Söderkvist, MD, PhD
PRINCIPAL INVESTIGATOR
Umeå University
Frequently Asked Questions
Who can join the NCT07524426 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bladder Cancer (BC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07524426 currently recruiting?
Yes, NCT07524426 is actively recruiting participants. Visit ClinicalTrials.gov or contact Umeå University to inquire about joining.
Where is the NCT07524426 trial being conducted?
This trial is being conducted at Umeå, Sweden.
Who is sponsoring the NCT07524426 clinical trial?
NCT07524426 is sponsored by Umeå University. The principal investigator is Karin Söderkvist, MD, PhD at Umeå University. The trial plans to enroll 248 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.